SCHEMBL7186451

SCHEMBL7186451

O=C(c1c(C(F)(F)F)cccc1C(F)(F)F)P(=O)(C(=O)c1c(Cl)ccc(Cl)c1Cl)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYK2 P29597 1/20 0.42
ITGB1 P05556 1/20 0.38
ITGA4 P13612 1/20 0.38
RORC P51449 7/20 0.36
PPARG P37231 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C9 P11712 2/20 0.36
CLCN2 P51788 1/20 0.36
GRM4 Q14833 1/20 0.36
PTGS2 P35354 1/20 0.35
CASR P41180 1/20 0.35
KDR P35968 1/20 0.35
POLB P06746 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
CTSS P25774 1/20 0.34
P2RX7 Q99572 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182186 0.91 TYK2 (0.48) TYK2ITGB1ITGA4RORCPPARG
SCHEMBL7182326 0.90 TYK2 (0.39) TYK2ITGB1ITGA4RORCPPARG
SCHEMBL7181377 0.90 TYK2 (0.40) TYK2ITGB1ITGA4RORCPPARG
SCHEMBL7186743 0.88 TYK2 (0.39) TYK2ITGB1ITGA4RORCPPARG
SCHEMBL7180976 0.85 TYK2 (0.43) TYK2ITGB1ITGA4RORCPPARG
SCHEMBL7189823 0.84 TSHR (0.41) TYK2CYP3A4HPGDSMN1; SMN2LMNA
SCHEMBL7175972 0.84 TYK2 (0.40) TYK2ITGB1ITGA4RORCGRM4
SCHEMBL7182312 0.84 ALDH1A1 (0.46) TYK2ITGB1ITGA4RORCSMN1; SMN2
SCHEMBL7188697 0.82 SLC6A9 (0.42) TYK2ITGB1ITGA4RORCCYP3A4
SCHEMBL7181415 0.80 TAS2R14 (0.41) TYK2HPGDLMNAGAACTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 TYK2 1285/4885ITGB1 2786/4885ITGA4 3521/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 TYK2 1333/4885ITGB1 3321/4885ITGA4 3643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.